scholarly journals High ZAP-70 expression correlates with worse clinical outcome in mantle cell lymphoma

Leukemia ◽  
2006 ◽  
Vol 20 (10) ◽  
pp. 1905-1908 ◽  
Author(s):  
D Hui ◽  
L Dabbagh ◽  
J Hanson ◽  
H M Amin ◽  
R Lai
1997 ◽  
Vol 99 (4) ◽  
pp. 842-847 ◽  
Author(s):  
E. Vandenberghe ◽  
C. De Wolf-Peeters ◽  
G. Vaughan Hudson ◽  
B. Vaughan Hudson ◽  
S. Pittaluga ◽  
...  

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4710-4710
Author(s):  
Carsten Schrader ◽  
Wolfram Klapper ◽  
Dirk Janssen ◽  
Paul Riis ◽  
Peter Meusers ◽  
...  

Abstract In malignant tumors beside cell proliferation also cell death plays role for cell survival. Apoptosis regulating genes can be divided into two groups: death antagonists and death agonists such as bax. The ratio of death agonists and antagonists determines if a cell goes into apoptosis. We investigated in a large collective the immunohistochemical expression of the apoptotic marker p53 and bax in relation to the clinical course. Biopsies were stained immunohistochemically with monoclonal antibodies against bax and p53 and the expression was subdivided in three groups: negative, weak positive and strong positive. The expression profiles were analyzed with the overall survival data according to Kaplan and Meier. Patients with mantle cell lymphoma that had negative p53 expression had a median overall survival time of 38.1 months compared to 22.3 months for patients with a weak and 11.3 months for a strong p53 expression (0<0.0001). The bax expression was in the majority of cases positive. Only one case showed a negative staining. Patients with weak and strong bax expression showed no differences in clinical outcome (median overall survival time: 23 vs 33 months, p=0.6051). The immunohistochemical detection of p53 in mantle cell lymphoma is a good predictor for the clinical outcome.


2013 ◽  
Vol 144 (5) ◽  
pp. S-757
Author(s):  
Jong-Yul Lee ◽  
In Seok Lee ◽  
Sung Jin Moon ◽  
Chul-Hyun Lim ◽  
Jin Su Kim ◽  
...  

1997 ◽  
Vol 15 (4) ◽  
pp. 1664-1671 ◽  
Author(s):  
A Majlis ◽  
W C Pugh ◽  
M A Rodriguez ◽  
W F Benedict ◽  
F Cabanillas

PURPOSE Clinical data and histologic material were retrospectively analyzed in 46 cases of previously untreated mantle cell lymphoma (MCL) to more fully characterize the clinical response pattern of these lymphomas and to determine whether growth pattern significantly affected clinical outcome. MATERIALS AND METHODS The histologic pattern was classified as diffuse (61%), nodular (13%), and mantle zone (26%) in accordance with stated criteria. RESULTS Bone marrow infiltration was detected in 69% of cases; the frequency of involvement correlated with histologic pattern, being most common in diffuse variants and least common in mantle zone variants. Other sites of extranodal involvement were observed in 50% of cases. Cyclin-D1 staining revealed nuclear positivity in 23 of 25 patients (92%) and no difference was observed between the various histologic patterns. Rearrangement at the bcl-1 major translocation cluster (MTC) was detected in seven of 21 cases, without regard for histologic pattern. Complete response rates to doxorubicin-based regimens showed a striking correlation with histologic pattern. Seventy-three percent of patients with a mantle zone pattern attained a complete response compared with only 25% of patients with a nodular pattern and 19% with a diffuse pattern. Three-year survival rates were 100%, 50%, and 55% for patients with mantle zone, nodular, and diffuse histologic patterns, respectively. CONCLUSION We conclude that (1) diffuse and nodular MCL are associated with a poor treatment response and a poor overall survival rate; (2) the mantle zone variant exhibits the clinical attributes of a low-grade lymphoma; and (3) the poor survival rates of patients with nodular and diffuse MCL suggest that these variants be classified as intermediate-grade lymphomas. However, the trend of the time to treatment failure curve does not indicate that current regimens can cure MCL.


Leukemia ◽  
2004 ◽  
Vol 18 (7) ◽  
pp. 1200-1206 ◽  
Author(s):  
C Schrader ◽  
P Meusers ◽  
G Brittinger ◽  
A Teymoortash ◽  
J-U Siebmann ◽  
...  

2005 ◽  
Vol 206 (3) ◽  
pp. 320-327 ◽  
Author(s):  
Sergio B Cogliatti ◽  
Francesco Bertoni ◽  
Dieter R Zimmermann ◽  
Samuel Henz ◽  
Tim C Diss ◽  
...  

2016 ◽  
Vol 55 (6) ◽  
pp. 531-540 ◽  
Author(s):  
Alejandro Roisman ◽  
Fuad Huamán Garaicoa ◽  
Fernanda Metrebian ◽  
Marina Narbaitz ◽  
Dana Kohan ◽  
...  

Hematology ◽  
2016 ◽  
Vol 2016 (1) ◽  
pp. 437-445 ◽  
Author(s):  
Eva Hoster ◽  
Christiane Pott

Abstract Despite the recent substantial improvement of clinical outcome in mantle cell lymphoma (MCL), resistance to immunochemotherapy and common relapses are challenges for long-term tumor control. The assessment of minimal residual disease (MRD) by real-time quantitative polymerase chain reaction has emerged as a widely feasible and standardized tool for direct assessment of therapy-induced reduction of tumor burden and regrowth after cytotoxic treatment in MCL, with much improved sensitivity compared with conventional staging procedures. Several studies have shown that intensification of initial treatment, which has resulted in improved clinical outcome, is immediately reflected in higher molecular remission rates; they have also shown that high-dose consolidation might not be able to compensate for less intensive induction regimens. Persistence or reappearance of MRD in clinical remission proved to be highly predictive for imminent clinical relapse associated with shorter overall survival. Therefore, the investigation of novel MRD-guided treatment strategies aimed at early eradication of MRD and pre-emptive treatment of molecular relapse seems warranted. Furthermore, the integration of MRD assessment into clinical response criteria could result in a more specific and potentially earlier end point for treatment efficacy. New technical developments such as high-throughput sequencing will further enhance the wide applicability of MRD detection in MCL.


Sign in / Sign up

Export Citation Format

Share Document